Charles River Laboratories, Inc. acquires Cognate BioServices and gene therapy division Cobra Biologics

Written by Vivian Xie

Laboratory servicer Charles River Laboratories, Inc. (MA, USA) has acquired cell and gene therapy contract development and manufacturing organization Cognate BioServices (TN, USA) and its gene therapy division Cobra Biologics. Charles River Laboratories supplies biomedical products and technology as well as research and development outsourcing services in the pharmaceutical, medical device and biotechnology industries. Cognate BioServices provides a range of services for regenerative medicine, cellular immunotherapy and cell therapy. The addition of the focused cell and gene therapy division is hoped to establish Charles River Laboratories as a leading scientific partner for cell and gene therapy development, testing and manufacturing....

To view this content, please register now for access

It's completely free